SPOTLIGHT -
Annual Conference Highlights New Research, Advances in ADHD
In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.
Watch
The Second Coming
"Things fall apart; the centre cannot hold; Mere anarchy is loosed upon the world..."
Unpacking Our Emotional Baggage in the New Year
Many social psychiatric challenges are worse, a year later...
Things You May Find Hidden in My Ear
"Spray the perfume of your smiles on the incision. Inject the song of life into my veins to wake me up. Gently beat the drum so my mind may dance with yours, my doctor, day and night."
'The One'
"...my eyes searching for the one skater in every crowd who glides graceful as a god, like my father years ago in his black leather racing skates..."
Building Psychiatric Capital in the New Year
You've heard of social capital and financial capital... but what about psychiatric capital?
Finding Meaning in Suffering: Helpful or Unnecessary?
Is finding meaning conducive to healing?
Midnight
"My black cat sprints through the kitchen door, a glassy-eyed cottontail hanging limp from his jaws."
"Thank You"
"Walk through the garden's dormant splendor. Say only, thank you."
My Jewish Influence on Serving the Underserved
Dr Moffic thanks those who fostered his faith.
ECT and Ketamine/Esketamine: Guiding Clinical Practice
ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.
Using Brain Science to Develop Better, Safer, More Effective Treatments
Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.
The First Step: A Schizophrenia-Specific Intervention for Nicotine Use
Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.
Amotivation in Individuals with Schizophrenia: Exciting Research Ideas at ACNP 2023 Annual Meeting
Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.
Final Pearls: Changing Possibilities in MDD Management
Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.
Clinical Insights: Second Case Analysis of MDD
Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.
Responding With Treatment: Clinical Perspectives on First MDD Case
Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.
Clinical Insights: First Case Analysis of MDD
Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.
Eating Disorders and Emerging Neuroscience
Don't miss this ACNP 2023 Annual Meeting session!
Examining New Agents for MDD Treatment (Esketemine)
Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Examining New Agents for MDD Treatment (Zuranolone)
Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Examining New Agents for MDD Treatment (AXS-05)
Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).
Love After Love
"You will love again the stranger who was your self."
Current Landscape of Rapid-Acting Therapies for MDD
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
Anhedonia and Cognitive Dysfunction: Glutamate Modulation's Impact
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
Shifting Paradigms: The Future Role of Rapid Acting Antidepressants
Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
Hopeful Horizons: The Potential of Rapid Acting Therapies in MDD
Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.
Targeting Glutamate Receptors in MDD Treatment
Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.
Giving Thanks to Those Who Furthered My Career
Who helped your career?
Cognitive Wellness: The Potential of Glutamate Modulation for MDD
Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.